. . . EXHIBIT 12.1 OSI PHARMACEUTICALS, INC. RATIO OF EARNING TO FIXED CHARGES NINE MONTHS NINE MONTHS ENDED ENDED JUNE 30, 2004 JUNE 30, 2003 2003 2002 2001 2000 1999 ------------- ------------- ------------- ------------- ------------ ------------ ----------- Net loss (137,182,413) (132,387,254) (181,357,335) (218,479,106) (23,755,434) (16,347,569) (9,798,437) Equity losses -- -- 243,455 347,820 200,000 Cummualtive effect of accounting change -- -- 2,625,000 ------------ ------------ ------------ ------------ ----------- ----------- ---------- Net loss before cumm effect and equity in investee (137,182,413) (132,387,254) (181,357,335) (218,479,106) (20,886,979) (15,999,749) (9,598,437) Add: Fixed charges 13,676,641 5,425,245 7,549,000 5,877,000 50,011 32,268 24,370 ------------ ------------ ------------ ------------ ----------- ----------- ---------- Net loss as adjusted (123,505,771) (126,962,009) (173,808,335) (212,602,106) (20,836,968) (15,967,481) (9,574,067) ============ ============ ============ ============ =========== =========== ========== 0 0 Fixed Charges: 0 0 Interest (gross), including amortization of issuance costs 13,676,641 5,425,245 7,549,000 5,877,000 50,011 32,268 24,370 Estimated interest portion of rent 0 0 0 0 0 0 0 ------------ ------------ ------------ ------------ ----------- ----------- ---------- Fixed charges 13,676,641 5,425,245 7,549,000 5,877,000 50,011 32,268 24,370 ------------ ------------ ------------ ------------ ----------- ----------- ---------- 0 0 Deficiency of earnings available to cover fixed charges (137,182,413) (132,387,254) (181,357,335) (218,479,106) (20,886,979) (15,999,749) (9,598,437) ============ ============ ============ ============ =========== =========== ==========